CircRNA Synthesis Market

CircRNA Synthesis Market Analysis

The CircRNA Synthesis Market size is estimated at USD 233.20 million in 2025, and is expected to reach USD 404.18 million by 2030, at a CAGR of 11.63% during the forecast period (2025-2030).

The market is witnessing significant innovation, driven by the distinct advantages of circRNAs, such as enhanced stability and prolonged protein expression. Recent advancements include the development of efficient circularization methods, optimization of internal ribosome entry sites to boost translation, and the engineering of circRNAs to improve therapeutic efficacy. In January 2024, CEPI partnered with scientists from the Houston Methodist Research Institute to advance the development of circular RNA (circRNA) vaccines. These vaccines offer superior stability, durability, and cost-effectiveness compared to conventional mRNA vaccines. Supported by USD 3.8 million in funding, the initiative aims to design and conduct preclinical evaluations of circRNA vaccine candidates, starting with Chikungunya, to establish proof of concept for this innovative vaccine platform. These innovations are unlocking novel applications in vaccines, gene regulation, and cell therapies.

Furthermore, biotechnology companies are increasingly investing in circRNA-based therapeutics and vaccines due to the inherent advantages of circular RNAs over linear mRNAs. These benefits include excellent stability, enhanced protein expression, and reduced manufacturing costs. For instance, in December 2024, Circio Holding ASA, a biotechnology company specializing in cutting-edge circular RNA technology for next-generation nucleic acid medicine, has successfully secured approximately NOK 10.7 million in funding. This significant financial support will drive the development and enhancement of their innovative circVec circular mRNA technology.

In addition, recent developments in the industry highlight the increasing importance of circRNA synthesis. Leading companies such as Circio, Sail Biomedicines, and Orna Therapeutics are actively exploring the therapeutic potential of circRNA. Their efforts focus on applications ranging from vaccines to advanced gene and cell therapies, leveraging circRNA's superior properties to address various medical challenges. These initiatives are driving the expansion of circRNA technology and contributing to market growth. For instance, in August 2024, Abogen Biosciences introduced the 'Cis-System, an advanced RNA circularization cis-splicing system designed to enhance the production of circular RNA.

However, there are high product costs and challenges in the production and delivery of circRNAs, expected to restrain market growth.

CircRNA Synthesis Market Trends

Reagents & kits Segment is Expected to Be Dominated the Market Over the Forecast Period

Advancements in reagent formulations and kit designs, such as improved enzymatic reactions and optimized buffers, are enhancing product reliability and usability. Simultaneously, the rising focus on circRNA-based therapeutics, particularly in oncology and vaccine development, is driving demand for these tools. To address this growing need, companies such as GenScript and New England Biolabs are actively expanding their reagent and kit portfolios, fueling growth in the circRNA synthesis industry.

For instance, in September 2023, GenScript Biotech Corporation enhanced its IVT mRNA synthesis portfolio by introducing customized circular RNA (circRNA) and lipid nanoparticles (LNPs) formulation services. These newly launched contract-manufactured reagent services are now available, reflecting GenScript's commitment to providing advanced reagents that drive progress in vaccine development, protein replacement therapies, and gene and cell therapies.

In November 2024, a study published by the National Library of Medicine introduced a transformative one-step synthesis system using E.coli for the mass production of circRNA. This method connects RNA sequences to group II intron elements and expresses them in HT115 cells, leading to improved yields while maintaining biological functionality. This advancement is driving significant growth in the market for reagents and kits used in circRNA synthesis, offering a more efficient and scalable solution for researchers and manufacturers alike.

Hence, due to the abovementioned factors, such as advancements in reagent formulations, innovative synthesis methods, and the increasing focus on circRNA-based therapeutics. With companies actively expanding their portfolios and groundbreaking research paving the way for scalable solutions, the market is well-positioned for sustained development in the coming years.

North America is Expected to Dominate the Pet Wheelchair Market

The growth is primarily driven by significant advancements in RNA-based therapeutics and the increasing prevalence of chronic diseases, including cancer and neurodegenerative disorders. For instance, according to the CDC, National Center for Chronic Disease Prevention and Health Promotion in February 2024, an estimated 129 million people in the United States have at least 1 major chronic disease including arthritis, diabetes, or heart disease. These conditions are disproportionately prevalent in socioeconomically disadvantaged areas, highlighting the critical need for innovative therapeutic solutions to address this growing healthcare burden.

In addition, in the United States, substantial investments from biotech firms and government funding are accelerating RNA research and implementing innovation. The United States National Science Foundation (NSF) and the National Institutes of Health (NIH) have partnered to fund new research aimed at developing RNA-based methods for biotechnology innovations. This collaboration has allocated over USD 12.7 million to nine research teams to explore the untapped potential of ribonucleic acid (RNA) for various biotechnology applications, such as disease prevention in crops and cancer therapies. Each team will receive between USD 1 million and USD 1.65 million through the Molecular Foundations for Biotechnology (MFB) program, a collaborative effort between NSF and the National Institutes of Health's National Human Genome Research Institute (NHGRI). Additionally, NHGRI plans to announce more projects in 2024, focusing on developing new technologies to study RNA biology. These efforts emphasize the growing emphasis on RNA research as a cornerstone for future biotechnological advancements.

Furthermore, the presence of leading industry players and a high volume of clinical trials targeting circRNA therapeutics are strengthening the circRNA synthesis industry's expansion in the Canada. Canadian researchers have played a pivotal role in understanding the basic mechanisms of RNA function and regulation. This includes pioneering work in RNA splicing, RNA interference, and the discovery of various RNA molecules. One of the most notable contributions is the development of mRNA vaccines, which were crucial in combating the COVID-19 pandemic. Canadian scientists were involved in the research and development processes that led to this vaccine. Canadian researchers continue to explore new frontiers in RNA science, including RNA therapeutics, RNA bioinformatics, and RNA-based technologies. These efforts are expected to lead to new medical and biotechnological applications

Therefore, owing to the factors mentioned above, the growth of the studied market is anticipated in the North American region.

CircRNA Synthesis Industry Overview

The CircRNA synthesis market is consolidated in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known include LGC Biosearch Technologies, Creative Biogene, SBS Genetech, Applied Biological Materials Inc., GenScript, Amerigo Scientific, BOC Sciences, GeneCopoeia, Inc., Guangzhou Geneseed Biotech. Co., Ltd., and Creative Biolabs among others.

CircRNA Synthesis Market Leaders

CircRNA Synthesis Market News

• November 2024: Circio Holding and Certest Biotec collaborated to develop lipid nanoparticles (LNPs) for targeted delivery of DNA vectors using Circio's circVec technology. They have successfully validated these formulations in vitro and will now test them in vivo over the next three to six months. If successful, this could lead to new treatments for genetic diseases.
• April 2024: Circio announced the success in vivo proof-of-concept for its circVec circular RNA platform technology. This achievement highlights the platform's potential in advancing gene therapy solutions, reinforcing Circio's strategic focus on innovation in the field.